PROCEPT BioRobotics (PRCT) News Today

Bank of America boosted their price objective on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a "buy" rating in a research report on Thursday.

PROCEPT BioRobotics (NASDAQ:PRCT) Shares Gap Up to $65.00

Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia

M&G Plc bought a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 139,462 shares of the company's stock, valued at approximately $8,507,000. M&G Plc owned approxima

Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Investment analysts at Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a research note issued on Friday, August 2nd. Leerink Partnrs analyst M. Kratky now forecasts that the company will

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.02. The firm had revenue of $53.35 million for the quarter, compared to the consensus estimate of $50.10 million. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The business's revenue was up 61.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.56) earnings per share.

Wells Fargo & Company boosted their price objective on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an "overweight" rating in a research note on Friday.

Truist Financial reaffirmed a "buy" rating and issued a $74.00 target price (down from $79.00) on shares of PROCEPT BioRobotics in a report on Friday.

Castleark Management LLC purchased a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 57,490 shares of the company's stock, valued at approximately

Price T Rowe Associates Inc. MD decreased its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,467,659 shares of the company's stock

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) saw unusually large options trading activity on Monday. Traders purchased 4,352 put options on the company. This is an increase of 1,092% compared to the average daily volume of 365 put options.

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 3.7%

Lord Abbett & CO. LLC raised its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 39.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 252,310 shares of the company's stock after purchasing an additi

Blair William & Co. IL acquired a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 429,793 shares of the company's stock, valued at approx

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 6%

Lisanti Capital Growth LLC reduced its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 17.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,655 shares of the company's stock after se

Mirae Asset Global Investments Co. Ltd. lessened its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 21.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 393,540 shares of the company's

Vanguard Group Inc. lifted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 2.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,184,585 shares of the company's stock after purchasing an ad

Wellington Management Group LLP raised its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 32.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,065,698 shares of the company's stock after buying an additional 26

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) EVP Alaleh Nouri sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $62.18, for a total value of $621,800.00. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $3,262,708.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts t

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) EVP Hisham Shiblaq sold 26,046 shares of the business's stock in a transaction on Monday, June 10th. The stock was sold at an average price of $68.24, for a total transaction of $1,777,379.04. Following the completion of the transaction, the executive vice president now owns 55,860 shares of the company's stock, valued at approximately $3,811,886.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Seven Eight Capital LP purchased a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 13,128 shares of the company's stock, valued at app

Point72 Europe London LLP raised its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 30.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530,071 shares of the company's stock after acquiring

PEAK6 Investments LLC raised its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 163.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,901 shares of the company's stock after acquiring an additi

Allianz Asset Management GmbH grew its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 42.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,635 shares of the company's stock

TD Asset Management Inc lowered its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 17.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 214,216 shares of the company's stock after selling 45,600 shares during the period. TD Ass

Rhenman & Partners Asset Management AB reduced its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 310,000 shares of the compa